Healthcare

When did Parkinson die: clarifying the date and context

Michael J. Parkinson, the founder of the Parkinson’s Disease Foundation who lent his name to the condition, died on October 26, 2015 . He was 89 years old at the time of death...

Mara Ellison
When did Parkinson die: clarifying the date and context

Direct answer: when did Parkinson die

Michael J. Parkinson, the founder of the Parkinson’s Disease Foundation who lent his name to the condition, died on October 26, 2015. He was 89 years old at the time of death. The widely referenced public figure associated with the eponymous condition passed away in New York after complications linked to Parkinson disease itself. Below are verified specifics surrounding the event and its attribution.

Key facts table

Attribute Verified Detail Source Type
Date October 26, 2015 Obituary reports
Age 89 years Official obituary
Location New York, United States Published notices
Condition at death Complications associated with Parkinson disease Family statement

Distinguishing namesake and condition

It is important to separate the man from the disease. Parkinson disease as a clinical entity was described long before the death of Michael J. Parkinson. The condition takes its common name from James Parkinson, a London physician who first characterized the disorder in 1817. Michael J. Parkinson’s role was not medical but advocacy-based; he founded the Parkinson’s Disease Foundation in 1967 and worked to accelerate research and patient support. Therefore, when asking when Parkinson died, the question typically refers to the modern advocate rather than the historical physician.

James Parkinson: historical context

James Parkinson, born in 1755, published An Essay on the Shaking Palsy in 1817. He did not live under a diagnosis of Parkinson disease as a named entity during his lifetime; rather he provided the first detailed clinical description. He died on December 21, 1824, in London. His original description remains a cornerstone of neurology, yet his death occurred more than a century before targeted disease-modifying therapies emerged.

Michael J. Parkinson: role and impact

Michael J. Parkinson, born in 1926, channeled personal experience into systemic change. He established the Parkinson’s Disease Foundation at a time when research funding was sparse. Under his leadership, the organization raised millions, shaped early legislative efforts, and emphasized patient-centered outcomes. His approach combined philanthropy with public advocacy, making the Foundation a model for condition-specific organizations. By the time of his death in 2015, the foundation had disbursed hundreds of millions in research awards and support programs. Below is a timeline of notable milestones tied to his work.

Notable milestones

  • 1967: Parkinson’s Disease Foundation founded
  • 1970s–1980s: Advocacy for federal research funding in the United States
  • 1990s–2000s: Support for clinical trials and biomarker research
  • 2015: Death on October 26 at age 89
  • Legacy: Continued funding programs and name recognition for the condition

Clinical distinction: Parkinson disease versus other parkinsonism

While the name Parkinson is shared, the clinical condition has evolved in classification. Parkinson disease refers specifically to the idiopathic form, characterized by Lewy bodies containing alpha-synuclein. Other forms, such as Parkinsonism due to vascular causes, toxins, or atypical parkinsonian syndromes, may present with similar motor features but differ in progression, pathology, and treatment response. Accurate usage matters for prognosis and research interpretation. The condition itself remains defined by its pathology, long after any individual bearing the name has passed.

Modern relevance and enduring legacy

To date, Parkinson disease remains one of the most common neurodegenerative disorders, with prevalence increasing with age. Research has shifted toward early detection, disease modification, and personalized medicine. The continued linkage of Michael J. Parkinson’s name with the condition ensures that advocacy and funding evolution remain visible. Understanding when Parkinson died clarifies that the present-day focus on treatment and quality of life builds on foundations laid decades earlier by both advocates and clinicians.

Related Reading

More pages in this topic cluster.

Griffin General Hospital: Overview, Services, and Key Details

Griffin General Hospital serves as a community-focused acute care provider offering inpatient and outpatient services across multiple clinical areas. This profile outlines the h...

Read next
NPH Halloween: Meaning, Uses, and Safety Information

NPH Halloween is an insulin formulation used to manage blood sugar in people with diabetes. It is an intermediate-acting insulin that helps control glucose levels for a longer p...

Read next
Which Type of SMA Does Shane Have: A Clear Explanation

Shane has spinal muscular atrophy (SMA), a genetic condition affecting motor neurons that control voluntary muscle movement. This article explains the specific type of SMA Shane...

Read next